Evidence map›Paper›PMID 35122151›Full record

ArticleMolecular genetics and genomics : MGG2022

Activating PIK3CA postzygotic mutations in segmental overgrowth of muscles with bone involvement in the body extremities.

Wen Tian, Liying Sun, Qi Zhang, Junhui Zhao, Yang Guo, Wenyao Zhong, Liu Liu, Katia Meirelles, Sha Tang, Jing Zhang and 9 more

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular genetics and genomics : MGG, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 5 institutions in 2 countries.

Wen Tian *Department of Hand Surgery, Clinical and Research Center for Congenital Hand Deformities and Rare Diseases, Beijing Jishuitan Hospital, Beijing, China.
Liying Sun *Department of Hand Surgery, Clinical and Research Center for Congenital Hand Deformities and Rare Diseases, Beijing Jishuitan Hospital, Beijing, China.
Qi ZhangKingMed Diagnostics, Guangzhou, Guangdong, China.
Junhui ZhaoDepartment of Hand Surgery, Clinical and Research Center for Congenital Hand Deformities and Rare Diseases, Beijing Jishuitan Hospital, Beijing, China.
Yang GuoDepartment of Hand Surgery, Clinical and Research Center for Congenital Hand Deformities and Rare Diseases, Beijing Jishuitan Hospital, Beijing, China.
Wenyao ZhongDepartment of Hand Surgery, Clinical and Research Center for Congenital Hand Deformities and Rare Diseases, Beijing Jishuitan Hospital, Beijing, China.
Liu LiuSema4, Branford, CT, USA.
Katia MeirellesPremier Research, Morrisville, NC, USA.
Sha TangKingMed Diagnostics, Guangzhou, Guangdong, China.
Jing ZhangKingMed Diagnostics, Guangzhou, Guangdong, China.
Yingzhao HuangPeking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.
Yuehan YinDepartment of Hand Surgery, Clinical and Research Center for Congenital Hand Deformities and Rare Diseases, Beijing Jishuitan Hospital, Beijing, China.
Nan ZhangDepartment of Hand Surgery, Clinical and Research Center for Congenital Hand Deformities and Rare Diseases, Beijing Jishuitan Hospital, Beijing, China.
Zongxuan ZhaoDepartment of Hand Surgery, Clinical and Research Center for Congenital Hand Deformities and Rare Diseases, Beijing Jishuitan Hospital, Beijing, China.
Qingyang LiDepartment of Hand Surgery, Clinical and Research Center for Congenital Hand Deformities and Rare Diseases, Beijing Jishuitan Hospital, Beijing, China.
Nan WuPeking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.
Ping FangKingMed Diagnostics, Guangzhou, Guangdong, China.
Fengqi ChangKingMed Diagnostics, Guangzhou, Guangdong, China. zb-changfengqi@kingmed.com.cn.ORCID http://orcid.org/0000-0002-5056-5451
Zhihong WuPeking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China. orthoscience@126.com.
Peking University · CNKingmed Diagnostics · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNPremier Research Group · USSema4 (United States) · US

Funding

beijing jishuitan hospital nova program XKXX201818beijing jst research funding 2019-YJ03beijing jst research funding ZR-201907capital's funds for health improvement and research 2020-4-40114non-profit central research institute fund of chinese academy of medical sciences 2019PT320025the national key research and development program of china 2016YFC0901500
6 · The paper itself

Abstract

Segmental overgrowth of the skeletal muscles with bone involvement in body extremities, predominantly affecting the upper limb, is an extremely rare condition with only 40-50 affected children described clinically. The molecular pathogenesis of this disorder remains largely unclear except for the identification of a somatic PIK3CA mutation in each of the six patients genetically tested, all restricted to upper limbs in the literature. This study aimed to further characterize the molecular defects for patients affected with segmental overgrowth of the skeletal muscles by analyzing a 9-gene panel selected from the PI3K/AKT/mTOR pathway and genes associated with other related conditions. Nineteen unrelated patients were chosen for this study, comprising ten upper limb (nine unilateral and one bilateral) and nine lower limb (eight unilateral and one bilateral) cases with variable bone involvement. In each case, an activating PIK3CA mutation (p.E110del, p.N345K, p.E542K, p.E545K, p.H1047R, or p.H1047L) was identified in the affected muscle tissue with variant allele frequencies ranging from 13.88 to 30.43%, while no mutation was detected in the paired peripheral blood sample, indicating somatic mosaicism. All detected mutations were limited to PIK3CA and were previously reported in other overgrowth syndromes currently categorized under the PIK3CA-Related Overgrowth Spectrum (PROS). Our study provides strong molecular evidence that isolated segmental overgrowth of the skeletal muscle with bone involvement is a subtype of PROS. Our findings expand the PROS clinical presentations with a newly molecularly classified condition and can provide guidance in clinical and molecular diagnosis and treatment for patients with this condition.

Indexed as

Bone DevelopmentClass I Phosphatidylinositol 3-KinasesGrowth DisordersMuscle, SkeletalPhosphatidylinositol 3-KinasesChildExtremitiesHumansMutationClass I Phosphatidylinositol 3-KinasesPhosphatidylinositol 3-KinasesPIK3CB protein, humanMuscular hypertrophyNext-generation sequencingOvergrowth syndromePIK3CASomatic mutations

Identifiers

PMID35122151
OpenAlexW4210368885

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.